Hot Stock
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000 % RENDITE!!
Anzeige

FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

0,51 USD
+6,25 %+0,03
24. Dec, 19:15:15 Uhr, UTP Consolidated
Kommentare 210
Summer.76
Summer.76, 01.03.2021 22:23 Uhr
0
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results http://www.globenewswire.com/news-release/2021/03/01/2184671/0/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million FDA to hold Advisory Committee Meeting on Roxadustat New Drug Application
Summer.76
Summer.76, 01.03.2021 22:22 Uhr
0
FibroGen EPS misses by $0.38, misses on revenue https://seekingalpha.com/news/3667889 • FibroGen (NASDAQ:FGEN): Q4 GAAP EPS of -$0.64 misses by $0.38. • Revenue of $64.99M (+715.4% Y/Y) misses by $35.83M. • Shares -17.3%.
Summer.76
Summer.76, 27.01.2021 18:36 Uhr
0
BRIEF-FibroGen Inc Entered Into A Supply Agreement With Astellas Pharma Europe Ltd On Jan. 13 https://pub.webull.com/us/news-html/b6d596de08104c34ac7963f93f2045eb.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en https://m.marketscreener.com/quote/stock/FIBROGEN-INC-18537026/news/FIBROGEN-INC-Entry-into-a-Material-Definitive-Agreement-form-8-K-32286087/
Summer.76
Summer.76, 24.12.2020 21:40 Uhr
0
https://seekingalpha.com/article/4396152-fibrogen-roxadustats-u-s-approval-2020-china-sales-and-outsized-growth
Summer.76
Summer.76, 22.12.2020 14:19 Uhr
0
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 https://www.globenewswire.com/news-release/2020/12/22/2149257/0/en/FibroGen-Advances-Phase-3-Clinical-Development-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-with-Initiation-of-ZEPHYRUS-2.html
Summer.76
Summer.76, 19.12.2020 7:37 Uhr
0
Fibrogen falls in post-market ahead of FDA decision https://seekingalpha.com/news/3645986-fibrogen-falls-in-post-market-ahead-of-fda-decision FibroGen Provides Regulatory Update on Roxadustat https://www.globenewswire.com/news-release/2020/12/18/2148127/0/en/FibroGen-Provides-Regulatory-Update-on-Roxadustat.html ...today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) by three months. The updated Prescription Drug User Fee Act (PDUFA) action date is March 20, 2021.  ...
Summer.76
Summer.76, 30.11.2020 21:11 Uhr
0
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication https://www.nasdaq.com/articles/fibrogens-fgen-evrenzo-approved-in-japan-for-another-indication-2020-11-30 FibroGen, Inc. FGEN, along with partner Astellas Pharma Inc. announced that it has received a second marketing approval for Evrenzo (roxadustat in Japan. The Japanese regulatory authority has now given a nod to roxadustat for the treatment of anemia of chronic kidney disease (“CKD” in adult patients who are not on dialysis. Notably, roxadustat was approved for the treatment of anemia caused by CKD in dialysis-dependent patients in September 2019. ...
Summer.76
Summer.76, 27.11.2020 13:13 Uhr
0
http://www.globenewswire.com/news-release/2020/11/27/2135245/0/en/Astellas-Receives-Approval-of-EVRENZO-roxadustat-in-Japan-for-the-Treatment-of-Anemia-of-Chronic-Kidney-Disease-in-Adult-Patients-Not-on-Dialysis.html
Summer.76
Summer.76, 05.11.2020 22:27 Uhr
0
FibroGen Reports Third Quarter 2020 Financial Results https://www.globenewswire.com/news-release/2020/11/05/2121451/0/en/FibroGen-Reports-Third-Quarter-2020-Financial-Results.html - Strong Third Quarter China Roxadustat Net Sales of $22.7 Million - ...
Summer.76
Summer.76, 03.11.2020 15:18 Uhr
0
https://pub.webull.com/us/news-html/2ed53ac64a2d4c70a7abbc5cb8a22fbf.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en&theme=1 FibroGen Inc (NASDAQ:FGEN) is a total spec and earnings won't matter, said Cramer. He likes the idea as long as investors put the stock in the total speculative column.
Summer.76
Summer.76, 22.10.2020 17:48 Uhr
0
https://www.globenewswire.com/news-release/2020/10/22/2112965/0/en/FibroGen-Presents-Late-Breaker-Abstract-Results-on-Associations-between-Hemoglobin-Levels-and-Cardiovascular-Outcomes-in-Roxadustat-Treated-Patients-with-Anemia-of-Chronic-Kidney-D.html
Summer.76
Summer.76, 03.09.2020 15:02 Uhr
0
https://endpts.com/akebia-shares-crater-as-their-phiii-anemia-drug-fails-on-safety-offering-rival-fibrogen-a-huge-advantage/ Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage
Summer.76
Summer.76, 11.08.2020 17:25 Uhr
0
https://www.globenewswire.com/news-release/2020/08/11/2076245/0/en/FibroGen-Announces-First-Patient-Enrolled-in-Pamrevlumab-Phase-3-Clinical-Trial-in-Patients-with-Duchenne-Muscular-Dystrophy.html
Adler.
Adler., 07.08.2020 16:23 Uhr
0
Huiii ✌️
Summer.76
Summer.76, 07.08.2020 15:47 Uhr
0
*** = investing_
Summer.76
Summer.76, 07.08.2020 15:46 Uhr
0
Mizuho Securities Stick to Their Buy Rating for FibroGen https://www.***/news/mizuho-securities-stick-to-their-buy-rating-for-fibrogen-2258082 ...setting a price target of 72, which is approximately 68.82% above the present share price of 42.65. ...
Meistdiskutiert
Thema
1 TESLA MOTORS Hauptdiskussion +5,70 %
2 NVIDIA Hauptdiskussion +3,60 %
3 MicroStrategy +5,40 %
4 Lilium Aktie +264,12 %
5 für alle, die es ehrlich meinen beim Traden.
6 DAX Hauptdiskussion +0,10 %
7 BTC/USD Hauptdiskussion +6,42 %
8 FREYR BATTERY ±0,00 %
9 BAYER Hauptdiskussion -0,58 %
10 AMAZON Hauptdiskussion +1,72 %
Alle Diskussionen
Aktien
Thema
1 TESLA MOTORS Hauptdiskussion +5,70 %
2 NVIDIA Hauptdiskussion +3,60 %
3 MicroStrategy +5,40 %
4 Lilium Aktie +268,39 %
5 BAYER Hauptdiskussion -0,58 %
6 FREYR BATTERY ±0,00 %
7 DPCM Capital Hauptdiskussion -2,76 %
8 MICRON TECHNOLOGY Hauptdiskussion -0,60 %
9 AMAZON Hauptdiskussion +1,72 %
10 FREYR Battery Inc Registered Shs Hauptdiskussion +16,02 %
Alle Diskussionen